The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

According to The Business Research Company’s Congenital Heart Disease (CHD) Global Market Report 2023, the congenital heart disease (CHD) market is expected to show promising growth in the forecast period.

Market Overview

• 2023 Market Size: $4.03 billion
• 2024 Projected Market Size: $4.42 billion
• CAGR (2023-2024): 9.7%

The congenital heart disease (CHD) market has experienced significant growth due to advancements in diagnostic and therapeutic technologies, increased awareness, and improved healthcare policies. The market is expected to continue expanding, reaching $6.43 billion by 2028.

Future Market Growth

• 2028 Projected Market Size: $6.43 billion
• CAGR (2024-2028): 9.8%

The expected growth is driven by increasing access to healthcare in developing regions, ongoing innovations in cardiac imaging, and rising global healthcare expenditures.

View More On The Congenital Heart Disease (CHD) Market Report 2024 –
https://www.thebusinessresearchcompany.com/report/congenital-heart-disease-chd-global-market-report

Key Drivers and Trends

• Maternal Diabetes Impact: The rise in maternal diabetes is a major driver for market growth. Gestational diabetes can increase the risk of congenital heart disease in infants. According to the CDC, the incidence of gestational diabetes increased from 6.0% to 8.3% from 2016 to 2021, highlighting the growing impact on CHD prevalence.
• Technological Innovations: The adoption of non-surgical heart valves, like the Harmony Transcatheter Pulmonary Valve (TPV) System by Medtronic, is transforming CHD treatment. This minimally invasive valve offers a non-surgical solution for patients with right ventricular outflow tract (RVOT) anomalies, improving patient outcomes and quality of life.
• Strategic Acquisitions: Venus MedTech’s acquisition of Cardiovalve Ltd. in December 2021 for $300 million is a significant market development. This acquisition enhances Venus MedTech’s capabilities in mitral and tricuspid valve replacement, positioning it as a leading player in structural heart treatments.

Market Segmentation

• By Type:
  • Heart Valve Defects
  • Heart Wall Defects
  • Blood Vessel Defects
  • Other Types
• By Diagnosis:
  • Electrocardiogram
  • Chest X-ray
  • Echocardiogram
  • Transesophageal Echocardiogram
  • Pulse Oximetry
  • Exercise Stress Test
  • Cardiac Computed Tomography (CT) Scan or Magnetic Resonance Imaging (MRI)
  • Cardiac Catheterization
  • Other Diagnosis
• By Treatment:
  • Interventional Cardiology
  • Cardiac Surgery
  • Telemedicine
  • Medication Management
  • Lifestyle Modifications
• By Age Group:
  • Infants
  • Children
  • Adolescents
  • Adults
• By Application:
  • Hospitals and Clinics
  • Diagnostic Centers
  • Ambulatory Surgical Centers
  • Research and Academic Institutions

Regional Insights

• North America: Was the largest market in 2023 due to advanced healthcare infrastructure and high adoption of new technologies.

Conclusion
The congenital heart disease market is poised for continued growth driven by technological advancements, increased awareness of maternal diabetes, and strategic industry moves. Innovations in non-surgical treatments and acquisitions of key players are likely to drive further expansion and improvements in patient care.

Request A Sample Of The Global Congenital Heart Disease (CHD) Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15545&type=smp